Company Announcements
Date
Title
7 February
31 December 2024 Interim Financial Report

5 February
STELFONTA® label extended in Great Britain

23 January
QBiotics strengthens medical leadership with appointment of CMO and world leading oncologist consultant

26 November
QBiotics receives $7.38m R&D tax incentive refund

22 November
2024 Annual General Meeting - CEO Presentation and Results of the Meeting

19 November
Bell Potter Healthcare Conference presentation

19 November
QBiotics Phase IIa Soft Tissue Sarcoma trial extended, following positive data presented at CTOS

19 November
QBiotics board changes

7 November
Mark Fladrich appointed Chair of QBiotics

5 November
Vale Dr Susan Foden, Non-executive Chair

23 October
QBiotics leadership transition

23 October
2024 Annual General Meeting

17 September
Preliminary data from QBiotics’ Phase IIa clinical trial in Soft Tissue Sarcoma presented at ESMO Congress 2024

12 September
QBiotics appoints world class Clinical Advisory Board

26 August
2024 Annual Report

23 August
August 2024 Shareholder Update

5 August
QBiotics welcomes Stephen Doyle as Chief Executive Officer

11 June
QBiotics Phase IIa clinical trial in Soft Tissue Sarcoma completion of patient recruitment

6 June
QBiotics receives $8.63m R&D tax incentive refund

31 May
May 2024 Shareholder Update

28 May
QBiotics to present at the 10th Annual Sachs Oncology Innovation Forum 2024 and BIO International Convention 2024

20 May
Board appointments at QBiotics Group

3 May
Tigilanol tiglate preclinical data published in Journal for ImmunoTherapy of Cancer

26 February
31 December 2023 Interim Financial Report

21 February
February 2024 Shareholder Update

16 February
QBiotics drug tigilanol tiglate awarded Orphan Drug Designation for patients with soft tissue sarcoma

23 November
Annual General Meeting Shareholder Presentation 2023

16 November
Board and Executive changes at QBiotics Group

16 October
New STELFONTA® data presented at the 2023 Veterinary Cancer Society Annual Conference

12 October
QBiotics to present advances from its oncology and wound healing programmes at key conferences in October and November

1 September
2023 Annual Report

18 August
August 2023 Shareholder Update

16 August
QBiotics’ tigilanol tiglate meets Primary Endpoints in its Phase I/IIa head and neck cancer dose escalation trial

9 June
First patient treated in QBiotics' Phase II clinical trial in patients with soft tissue sarcoma

8 June
BIO International Convention presentation

2 June
Sachs 9th Annual Immuno-Oncology Innovation Forum presentation

31 May
QBiotics to present at Sachs 9th Annual Immuno-Oncology Innovation Forum and the BIO International Convention

30 May
Changes to the Board of Directors

29 May
May 2023 Shareholder Update

24 April
QBiotics opens Phase II clinical trial to investigate the preliminary efficacy of Tigilanol Tiglate in soft tissue sarcoma

29 March
First patient treated in QBiotics’ Phase II Clinical Trial treating head and neck cancer with tigilanol tiglate

7 March
31 December 2022 Interim Financial Report

14 February
QBiotics announces amended human clinical strategy for tigilanol tiglate and Non-executive Director resignation

22 December
QBiotics Poster Presentation at SITC 2022

11 December
Update of QBiotics Group human oncology clinical trials

8 December
QBiotics appoints new Chair and Deputy Chair

2 December
Resignation of non-executive chair

21 November
Annual General Meeting CEO Presentation 2022

13 September
30 June 2022 Annual Report

25 July
FDA approves IND to initiate soft tissue sarcoma (STS) trial

22 March
COVID-19 impact update

14 March
31 December 2021 Interim Financial Report

2 March
Phase I/II trial (QBC46-H03) completes recruitment

15 December
STELFONTA® launches in Australia

7 July
APVMA approves registration of STELFONTA

28 June
QBiotics concludes successful $85 million capital raise

3 June
First patient dosed in QBiotics and MSD clinical trial collaboration for unresectable melanoma

25 May
Prospectus – Offer opens and Application Forms now available

17 May
QBiotics lodges Prospectus in preparation for share offer to Existing Shareholders

20 April
QBiotics raises AU$22.55 million from existing Sophisticated Investors

9 April
Hamish Corlett joins the Board of QBiotics

1 April
QBiotics announces plan to increase capital raise to up to AU$85 million

16 March
Cornerstone Investor Joins QBiotics

16 March
QBiotics announces plan to raise up to AU$75 million

16 March
QBiotics welcomes TDM Growth Partners as cornerstone investor

24 February
QBiotics’ first USA shipment of STELFONTA®

1 February
Nicholas Moore joins the Board of QBiotics

17 November
FDA approves registration of STELFONTA®

21 September
STELFONTA® USA Marketing Authorisation Progress

13 August
QBiotics announces clinical collaboration with MSD targeting unresectable melanoma

22 July
QBiotics doses first Australian patient in Phase I/II clinical trial for head and neck cancer

17 June
Pivotal canine field study results published in The Journal of Veterinary Internal Medicine reveal STELFONTA® (tigilanol tiglate) removes 75% of tumours

27 April
QBiotics commercialises first tigilanol tiglate pharmaceutical product with launch of STELFONTA®

February
QBiotics raises AU$17.76 million from Sophisticated Investors

20 January
QBiotics receives first registration for tigilanol tiglate with European Medicines Agency approval of STELFONTA®

10 December
The first in-human Clinical Phase I study of intratumoural tigilanol tiglate has been published in The Lancet's EBioMedicine journal

3 December
QBiotics announces first patient dosed in its Phase I/II clinical trial of tigilanol tiglate for head and neck cancer

November
STELFONTA Progress with European Medicines Authority

14 October
Dr Susan Foden joined the Board of QBiotics

October
Scientific Presentations: Veterinary Cancer Society, Houston, USA

September
Tigilanol tiglate canine mast cell tumour (MCT) pivotal field efficacy clinical trial results presented at prestigious international congresses

April
International Publication - Tigilanol Tiglate Canine Dose Characterisation Study
